[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-or-plasmacytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-or-plasmacytoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100549583","phase-1-engineered-dendritic-cell-vaccines-for-multiple-myeloma-100549583",false,"NCT06435910","Engineered Dendritic Cell Vaccines for Multiple Myeloma","Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients","Inclusion Criteria:\n\n* Male and female subjects with multiple myeloma or plasmacytoma\n* Very good partial or complete remission (CR) after prior combination therapies.\n* Expected survival \\> 12 weeks\n* Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal\n* Voluntary informed consent is given with willingness to continue follow up\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Uncontrolled active infection\n* HIV or active hepatitis B or hepatitis C infection\n* Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary","ALL","18 Years","80 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.",[27],"Multiple Myeloma or Plasmacytoma",[29,30,31],"MM","CAR T","DC vaccine","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":36},"2024-05-11",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Shenzhen Geno-Immune Medical Institute","OTHER"]